News

The U.S. Food and Drug Administration (FDA) is poised to soon issue a final determination on Yutrepia, an inhaled dry powder formulation of treprostinil, up for approval to treat both pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).

The FDA granted Yutrepia tentative approval for PH-ILD last year and for PAH in 2021. These tentative approvals meant that the FDA judged that Yutrepia met all criteria for quality, safety, and efficacy, but the therapy was not able to be brought to market. read more

Pulmonary hypertension (PH) is associated with an increased risk for sleep disorders, including obstructive sleep apnea, and structural brain changes at the genetic level, according to a recent study.

These findings may help “develop new guidelines for the clinical management, personalized diagnosis, and treatment of PH, sleep disorder diseases, and their associated neurological comorbidities [coexisting disorders],” researchers wrote.

The study, “Triangular Causality Among Pulmonary Hypertension, Sleep Disorders, and Brain Structure at the Genetic Level: A Mendelian Randomization Study Focused on the Lung-Brain Axis,” was published in Nature and Science of Sleep. read more

Following my heart and lung transplant in 2018, I really wanted a smartwatch. Admittedly, the dream was that I’d be using this piece of tech to track ambitious hikes and long walks. Maybe even runs. I had a very athletic vision of myself following recovery, which, of course, ended up not being my reality.

Still, I got a smartwatch, and it’s proven to be a helpful accessory in my post-transplant life. It’s just one of the many ways I rely on modern technology to keep track of my health and simplify my day-to-day activities. read more